Stockscreener 앱 받기
33.37
2.80%
0.91
시간 외 거래:
33.37
전일 마감가:
$32.46
열려 있는:
$32.71
하루 거래량:
264.17K
Relative Volume:
0.73
시가총액:
$617.41M
수익:
$299.77M
순이익/손실:
$364.23M
주가수익비율:
1.7825
EPS:
18.7211
순현금흐름:
$79.27M
1주 성능:
+7.96%
1개월 성능:
+15.03%
6개월 성능:
-20.43%
1년 성능:
+74.16%
1일 변동 폭
$32.71
$34.39
1주일 범위
$30.77
$34.39
52주 변동 폭
$18.14
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
33.37 | 618.34M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals (RIGL) Advances 2.13%: Testing Resistance at $32.26Leveraged ETF Flow - newsline.com
RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart - ChartMill
Why (RIGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Rigel Pharmaceuticals Edges Higher: Testing Key Resistance at $31.61Gap Up Stocks - newsline.com
Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals - Benzinga
Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes - Stock Titan
Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations - Stock Titan
Rigel (RIGL) CMO uses 850 shares to cover stock tax liability - Stock Titan
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
Rigel Pharmaceuticals Gains Momentum, Testing Key Resistance at $32.14Straddle Setup - newsline.com
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar - GuruFocus
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Pharmaceuticals Inc (RIGL) - GuruFocus
Understanding Momentum Shifts in (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade - Stock Titan
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - Yahoo Finance
Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference - GuruFocus
Rigel Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 27, 2026 - geneonline.com
Rigel (RIGL) Gains Momentum as Kissei Submits NDA for Rezlidhia in Japan - GuruFocus
Rigel Pharmaceuticals (RIGL) Gains Nearly 2% as Stock Tests Key Resistance Near $31.24High Reward Trades - thelegaladvocate.com
Rigel Pharmaceuticals Acquires Global Rights to Veppanu in $85 Million Deal, Targeting ESR1-Mutated Breast Cancer - geneonline.com
Biotech CEO to give Rigel company overview at Jefferies healthcare conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference – Company Announcement - Financial Times
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Technical Analysis | Trend, Signals & Chart Patterns | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress - PR Newswire
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Shareholders Approve Equity Plans and Board Slate - TipRanks
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting - Stock Titan
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs - TipRanks
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead - simplywall.st
Board member gets 5,750 RSUs at Rigel Pharmaceuticals (RIGL) - Stock Titan
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - MSN
Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Q3 2025 Earnings Preview - MSN
Director Walter H. Moos receives 5,750-share RSU award at RIGEL (NASDAQ: RIGL) - Stock Titan
Avoiding Lag: Real-Time Signals in (RIGL) Movement - Stock Traders Daily
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU - simplywall.st
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake - Stock Titan
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rigel Pharmaceuticals 주식 (RIGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ali-Jackson Kamil | Director |
May 26 '26 |
Sale |
29.17 |
2,500 |
72,925 |
12,625 |
2.60%
0.94%
자본화:
|
볼륨(24시간):